B
BVF Partners L.P.
+ HoldingFDMT
+11.78%
3M Return
$14.670
-0.236 (-1.61%)終値時点
Loading chart…
- High
- 15.000
- Open
- 14.915
- VWAP
- 14.62
- Vol
- 1.10M
- Mkt Cap
- 1.08B
- Low
- 14.200
- Amount
- 16.10M
- EV/EBITDA, TTM
- 1.44
4D Molecular Therapeutics, Inc. is a late-stage biotechnology company advancing durable and disease-targeted therapeutics. The Company's lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. Its lead indication for 4D-150 is wet age-related macular degeneration, which is in Phase III development, and second indication is diabetic macular edema. The Company is developing 4D-710 for the treatment of a range of people with cystic fibrosis independent of their specific CFTR mutation. 4D-710 is an investigational genetic medicine candidate using the A101 vector for the treatment of cystic fibrosis lung disease. The Company's non-core programs include 4D-175, 4D-725, and 4D-310.
バリュエーション指標
The current forward P/E ratio for 4D Molecular Therapeutics Inc (FDMT) is -1.26, compared to its 5-year average forward P/E of -4.89.
Whales holding FDMT
イベントタイムライン
ニュース
2.008-18stocktwitsOCUL and FDMT Stocks Surge on EyePoint Trial Setback
8.507-24NASDAQ.COMBiotech Sector Highlights: Regulatory Approvals and Restructuring
9.007-20seekingalpha4D Molecular Therapeutics Releases Positive Two-Year Data for AMD Candidate 4D-150
9.007-20NASDAQ.COM4D Molecular Therapeutics Reports Positive 2-Year PRISM Trial Data
9.007-18NewsfilterPositive Two-Year Data for 4D-150 in Wet AMD Clinical Trial
FDMT FAQ — answered by Alphio AI
4D Molecular Therapeutics, Inc. is a late-stage biotechnology company advancing durable and disease-targeted therapeutics. The Company's lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. Its lead indication for 4D-150 is wet age-related macular degeneration, which is in Phase III development, and second indication is diabetic macular edema. The Company is developing 4D-710 for the treatment of a range of people with cystic fibrosis independent of their specific CFTR mutation. 4D-710 is an investigational genetic medicine candidate using the A101 vector for the treatment of cystic fibrosis lung disease. The Company's non-core programs include 4D-175, 4D-725, and 4D-310. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。